Iraqi H5N1 case confirms diagnostic challenges:
This article was originally published in Clinica
Executive Summary
The demands placed upon diagnostic technologies in relation to controlling the avian flu virus H5N1 were highlighted again today, when the WHO retrospectively confirmed as positive Iraq's third case of the disease. The case, which was reported last March in Baghdad, presented with a mild form of the disease and recovered, but external verification tests proved inconclusive, probably as a result of sample deterioration in light of shipment difficulties. However, "repeated testing, using different methods, was needed for diagnostic confirmation," said the WHO. Two cases had been confirmed as H5N1 in January.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.